Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger Inc (NQ: SDGR )

20.84 +0.47 (+2.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Not Quite a Bailout: So Much Banking News to Discuss
Plus, two Motley Fool analysts share their insight on a pair of stocks to watch. 
Via The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
MarketBeat Week in Review – 3/6 - 3/10
Stocks are down sharply to end the week, and the MarketBeat staff continues to show investors why dividend stocks need to be part of your playbook 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Analyst Expectations for Schrodinger's Future
Via Benzinga
Why Shares of Schrödinger Were Up Today
The company delivered a nice earnings surprise. 
Via The Motley Fool
Citigroup Maintains Buy Rating for Schrodinger: Here's What You Need To Know
Via Benzinga
4 Analysts Have This to Say About Schrodinger
Via Benzinga
3 Amazing AI Stocks for Your March Buy List
With the Street catching onto the transformational power of AI, these amazing AI stocks are very well-positioned to climb tremendously. 
Via InvestorPlace
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results
From Schrödinger, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
3 AI Stocks to Buy for the Future of Automation
Increased appreciation for AI and the Street's reduced hostility to growth stocks make this a good time to find AI stocks to buy. 
Via InvestorPlace
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
From Schrödinger Inc.
Via Business Wire
Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28
From Schrödinger
Via Business Wire
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a... 
Via Talk Markets
Schrödinger to Present at SVB Securities Global Biopharma Conference
From Schrödinger
Via Business Wire
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... 
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities
From Schrödinger, Inc.
Via Business Wire
Why These 7 Healthcare Stocks Could Soar in 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
7 Drug Stocks That Will Soar in 2023
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years. 
Via InvestorPlace
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting
From Schrödinger
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 49 companies made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.